Sanofi and Aqemia have reached a $140 million drug research agreement
芊芊551
发表于 2023-12-5 16:12:28
290
0
0
On December 5th, French pharmaceutical company Aqemia issued a statement stating that it has reached a multi-year research cooperation agreement with Sanofi worth up to $140 million. Aqemia will use its generative artificial intelligence and deep physics algorithms and platform to design new drug molecules.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
You may like
- Nvidia CEO Huang Renxun continues to sell shares, reportedly selling stocks worth nearly $500 million in total
- AstraZeneca and Sinopharm Group reach nearly $2 billion cardiovascular drug authorization agreement
- Trump elected to lead Tesla stock price, Musk's net worth skyrockets overnight by $20.9 billion
- Ali Wu Yongming: AI will create great value far beyond the Internet in the next 30 years
- Zhihu and Tencent renew framework agreement
- Musk suddenly went viral! Worth over $360 billion, Bank of America raises Tesla target price
- Zhihu Yanyan Story releases 2024 Short Story Influence List, IP development value continues to amplify
- Beike terminates its agreement to acquire equity in Space Intelligence
- Kaken signs Stat6 global licensing agreement with Johnson&Johnson
- Jianxun Daily | Hengrui Pharmaceutical and IDEAYA signed an authorization agreement; Liu Zhongliang, the actual controller of Weikang Pharmaceutical, has been registered